We previously wrote about Genentech’s U.S. Patent No. 6,407,213 (“the ’213 patent”) to Carter, first in October 2017, and more...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Boehringer Ingelheim
-
-
The August 2018 Update to the PTAB Trial Practice Guide added guidance regarding the Patent Trial and Appeal Board’s (“the Board”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
U.S. Patent No. 8,329,172 (“the ’172 patent”), a Biogen-owned patent covering a treatment regime for low-grade B-cell non-Hodgkin’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, Celltrion, Inc. (“Celltrion”) filed a copycat IPR petition directed against U.S. Patent No. 7,976,838 (“the ʼ838...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported, Pfizer filed three IPR petitions against Biogen-owned patents claiming methods of treatment with rituximab in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On November 6, 2017, Sandoz, Inc. filed its eighth inter partes review (“IPR”) against AbbVie Biotechnology Ltd. (“AbbVie”),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Samsung Bioepis (“Bioepis”) has joined a growing list of challengers to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Recently, AbbVie, Inc. and AbbVie Biotechnology, LTD (collectively “AbbVie” or “Plaintiffs”) filed a Complaint in the United States...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]